Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAME-CD: Antibiotics plus FMT in Active Crohn's Disease
jRCTs031250169Recruiting
- Start
- Jan 2026
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of amoxicillin, fosfomycin, metronidazole and allogeneic fecal microbiota in Crohn's disease. Primary endpoint: Clinical response rate at week 8 after FMT. Started Jan 2026; status: recruiting.
02
Drugs
amoxicillinfosfomycinmetronidazoleallogeneic fecal microbiota
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCTs031250169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250169.